Bacterial co-infections in cancer patients with COVID-19: predictors and antimicrobial resistance trends

Rasha M Abdel-Hamid; Ahmed Bayoumi; Mona S Abdellateif; Hend A Nooh; Lobna Refaat; Eman Z Kandeel; Safaa S Hassan

doi:10.3855/jidc.19731

Bacterial co-infections in cancer patients with COVID-19: predictors and antimicrobial resistance trends

Authors

Rasha M Abdel-Hamid Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt https://orcid.org/0000-0002-2177-6153
Ahmed Bayoumi Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt https://orcid.org/0009-0000-0086-1466
Mona S Abdellateif Medical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt https://orcid.org/0000-0002-5510-4435
Hend A Nooh Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Lobna Refaat Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Eman Z Kandeel Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Safaa S Hassan Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3855/jidc.19731

Keywords:

Critical and severe COVID-19, multidrug-resistant, co-infections, secondary infections, cancer patients

Abstract

Introduction: Within the context of the coronavirus disease 2019 (COVID-19) pandemic, this study investigated the multifaceted challenges of bacterial infections in cancer patients with COVID-19. It focuses on clinical predictors, resistance patterns, and microbiological characteristics.

Methodology: Over 18 months, 112 adult cancer patients with coronavirus infection confirmed by reverse transcription polymerase chain reaction (RT-PCR) were enrolled. Bloodstream and respiratory samples were evaluated for bacterial infection using the Phoenix automation system for definitive species identification. In vitro susceptibility testing followed the Clinical Laboratory Standards Institute (CLSI) M100-Ed30 guidelines.

Results: Bacterial infections affected 25.0% of patients, encompassing bacteremia (21.4%) and respiratory tract infections (8.0%). Multivariable analysis identified hypertension, age < 60, and critical COVID-19 as significant predictors for bacterial infections (p-values = 0.024, 0.029, and 0.039, respectively). Most patients received antimicrobial therapy (93.8%), including last-resort carbapenems (52.7%) and colistin (8.9%). Thirty-three bacterial isolates were identified, with secondary infections doubling co-infection rates. Escherichia coli, Klebsiella species, and Staphylococcus aureus were the most common co-infecting species, while Klebsiella, Acinetobacter, and Pseudomonas species were more frequently associated with secondary infections. Alarmingly, 84.8% of isolates displayed high resistance patterns. All isolated S. aureus species were methicillin-resistant, and 62.5% of Gram-negative bacteria were exclusively sensitive to colistin.

Conclusions: The dominance of highly transmissible hospital-acquired bacterial species, with increased resistance and extensive antibiotic use in COVID-19 patients, necessitates strict infection control and antimicrobial stewardship. Developing customized antimicrobial strategies for cancer patients with COVID-19 is crucial to managing bacterial infections effectively and improving patient outcomes.

Downloads

Published

2024-08-31

How to Cite

Abdel-Hamid RM, Bayoumi A, Abdellateif MS, Nooh HA, Refaat L, Kandeel EZ, Hassan SS (2024) Bacterial co-infections in cancer patients with COVID-19: predictors and antimicrobial resistance trends. J Infect Dev Ctries 18:1185–1195. doi: 10.3855/jidc.19731

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 18 No. 08: August 2024

Section

Coronavirus Pandemic

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).